• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌的分子亚型与Ki-67指数,特别关注三阴性乳腺癌。在一家三级护理中心进行的为期3年的研究。

Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center.

作者信息

Pai Shweta, Murthy Srinivasa V

机构信息

Department of Pathology, ESIC Medical College and Post Graduate Institute of Medical Science and Research, Rajajinagar, Bangalore, India.

出版信息

Indian J Surg Oncol. 2025 Apr;16(2):478-490. doi: 10.1007/s13193-023-01773-1. Epub 2023 May 30.

DOI:10.1007/s13193-023-01773-1
PMID:40337051
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12052743/
Abstract

PURPOSE

Molecular subtyping of breast carcinoma and Ki-67 index has gained prominence in the recent past, as conventional factors such as surgical margins, tumor size, grade and lymph node involvement, are not sufficient to assess prognosis and make better therapeutic decisions. These subtypes include Luminal A, Luminal B, Triple Negative breast cancer (TNBC), and HER2-enriched subtypes. This study aimed to analyze the molecular subtypes and Ki-67 index in prognosis of breast carcinoma.

METHOD

This retrospective study was conducted in the department of Pathology in a tertiary care center over a period of 3 years. All invasive breast carcinomas (IDC) which were molecularly subtyped and Ki-67 indexed were included in the study. Statistical analysis was done using SPSS software.

RESULTS AND DISCUSSION

Out of 253 cases, 231 cases (91.3%) were IDC-NST and 22 cases (8.7%) were special types. Metaplastic and papillary tumors were associated with higher grade and high Ki-67 value. TNBC (35.2%) showing a majority of high-grade tumors, was the most prevalent subtype followed by Luminal A (32%) showing low grade, unlike other studies which showed luminal A to be most common subtype. The rare PR positive subtype was also observed in our study.

CONCLUSION

TNBC and HER 2-positive subtypes exhibited bad prognosis with higher histological grade, high Ki-67 index and higher age at presentation whereas Luminal A subtype, with lower grade and low Ki-67 index showed better prognosis. Thus, this vast array of predictive and prognostic information obtained by molecular subtyping will help clinicians in not only distinguishing between low-risk and high-risk subtypes but also in customization of the treatment and follow-up of the patients.

摘要

目的

近年来,乳腺癌的分子亚型和Ki-67指数备受关注,因为诸如手术切缘、肿瘤大小、分级和淋巴结受累等传统因素不足以评估预后并做出更好的治疗决策。这些亚型包括管腔A型、管腔B型、三阴性乳腺癌(TNBC)和HER2富集型。本研究旨在分析乳腺癌预后中的分子亚型和Ki-67指数。

方法

本回顾性研究在一家三级医疗中心的病理科进行,为期3年。所有进行了分子亚型分类和Ki-67指数测定的浸润性乳腺癌(IDC)均纳入研究。使用SPSS软件进行统计分析。

结果与讨论

在253例病例中,231例(91.3%)为浸润性非特殊型癌(IDC-NST),22例(8.7%)为特殊类型。化生型和乳头状肿瘤与高级别和高Ki-67值相关。TNBC(35.2%)显示大多数为高级别肿瘤,是最常见的亚型,其次是管腔A型(32%),显示为低级别,这与其他显示管腔A型为最常见亚型的研究不同。在我们的研究中还观察到了罕见的孕激素受体(PR)阳性亚型。

结论

TNBC和HER2阳性亚型表现出不良预后,具有更高的组织学分级、高Ki-67指数和更高的发病年龄,而管腔A型亚型,具有较低的分级和低Ki-67指数,显示出较好的预后。因此,通过分子亚型分类获得的大量预测和预后信息不仅将帮助临床医生区分低风险和高风险亚型,还将有助于患者治疗和随访的个性化定制。

相似文献

1
Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center.乳腺癌的分子亚型与Ki-67指数,特别关注三阴性乳腺癌。在一家三级护理中心进行的为期3年的研究。
Indian J Surg Oncol. 2025 Apr;16(2):478-490. doi: 10.1007/s13193-023-01773-1. Epub 2023 May 30.
2
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
3
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
Correlation of Radiological and Pathological Tumor Sizes in Breast Cancer Based on Molecular Subtypes and Accompanying DCIS: A Retrospective Multicenter Study.基于分子亚型和伴发导管原位癌的乳腺癌放射学与病理学肿瘤大小的相关性:一项回顾性多中心研究
Acad Radiol. 2025 Jun;32(6):3511-3518. doi: 10.1016/j.acra.2025.01.037. Epub 2025 Feb 20.

本文引用的文献

1
Molecular classification of breast cancer: A retrospective cohort study.乳腺癌的分子分类:一项回顾性队列研究。
Ann Med Surg (Lond). 2019 Dec 6;49:44-48. doi: 10.1016/j.amsu.2019.11.021. eCollection 2020 Jan.
2
Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use.乳腺癌免疫组织化学特征用于预后评估及治疗的研究
Niger J Surg. 2018 Jul-Dec;24(2):100-106. doi: 10.4103/njs.NJS_2_18.
3
Molecular Subtypes and Local-Regional Control of Breast Cancer.乳腺癌的分子亚型与局部区域控制
Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. doi: 10.1016/j.soc.2017.08.005.
4
Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program.酒精、身体活动、吸烟与挪威乳腺癌筛查计划中大型巢式病例对照研究的乳腺癌亚型。
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1736-1744. doi: 10.1158/1055-9965.EPI-17-0611. Epub 2017 Sep 6.
5
Ki-67 as a prognostic marker according to breast cancer molecular subtype.Ki-67作为一种根据乳腺癌分子亚型的预后标志物。
Cancer Biol Med. 2016 Dec;13(4):496-504. doi: 10.20892/j.issn.2095-3941.2016.0066.
6
How could breast cancer molecular features contribute to locoregional treatment decision making?乳腺癌分子特征如何有助于局部区域治疗决策?
Crit Rev Oncol Hematol. 2017 Feb;110:43-48. doi: 10.1016/j.critrevonc.2016.12.006. Epub 2016 Dec 8.
7
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.管腔型乳腺癌预后评估的最佳Ki67截断值:一项长期随访的大型病例系列研究
Breast Cancer Res Treat. 2016 Jun;157(2):363-371. doi: 10.1007/s10549-016-3817-9. Epub 2016 May 7.
8
An overview of triple-negative breast cancer.三阴性乳腺癌概述。
Arch Gynecol Obstet. 2016 Feb;293(2):247-69. doi: 10.1007/s00404-015-3859-y. Epub 2015 Sep 4.
9
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.定制疗法——改善早期乳腺癌的管理:2015年早期乳腺癌初始治疗圣加仑国际专家共识
Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4.
10
Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.根据 Ki-67、肿瘤大小和孕激素受体阴性对 Luminal A 和 Luminal B 亚型进行区分,提供预后信息。
Clin Med Insights Oncol. 2014 Sep 11;8:107-11. doi: 10.4137/CMO.S18006. eCollection 2014.